Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control studyMargherita Rimini, Andrea Casadei‐Gardini, Caterina Soldà et al.|Hepatology Research|2021Cited by 46
Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteriaHironori Ochi, Kouji Joko, Atsushi Hiraoka et al.|Journal of Gastroenterology|2020Cited by 45
Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinomaYohei Koizumi, Yoichi Hiasa, Masashi Hirooka et al.|Endocrine Journal|2019Cited by 39
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinomaAtsushi Yukimoto, Yoichi Hiasa, Masashi Hirooka et al.|Japanese Journal of Clinical Oncology|2018Cited by 35
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinibIlario Giovanni Rapposelli, Margherita Rimini, Toshifumi Tada et al.|Liver International|2021Cited by 25